![Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection | British Journal of Cancer Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2017.473/MediaObjects/41416_2018_Article_BFbjc2017473_Fig1_HTML.jpg)
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection | British Journal of Cancer
![Study design with overlapping SAD-MAD cohorts, where treatment periods... | Download Scientific Diagram Study design with overlapping SAD-MAD cohorts, where treatment periods... | Download Scientific Diagram](https://www.researchgate.net/publication/299547400/figure/fig1/AS:614240520007685@1523457760729/Study-design-with-overlapping-SAD-MAD-cohorts-where-treatment-periods-took-place-in-a.png)
Study design with overlapping SAD-MAD cohorts, where treatment periods... | Download Scientific Diagram
![Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)](https://mma.prnewswire.com/media/370141/regulus_logo_finalnew_Logo.jpg?p=facebook)
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Adaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient
![Safety, tolerability of ES16001, a novel varicella zoster virus reactivation inhibitor, in healthy adults | European Journal of Medical Research | Full Text Safety, tolerability of ES16001, a novel varicella zoster virus reactivation inhibitor, in healthy adults | European Journal of Medical Research | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs40001-021-00565-z/MediaObjects/40001_2021_565_Fig1_HTML.png)
Safety, tolerability of ES16001, a novel varicella zoster virus reactivation inhibitor, in healthy adults | European Journal of Medical Research | Full Text
![Study design. Subjects in SAD cohort 4, part 2, were dosed in the fed... | Download Scientific Diagram Study design. Subjects in SAD cohort 4, part 2, were dosed in the fed... | Download Scientific Diagram](https://www.researchgate.net/publication/354425740/figure/fig2/AS:1085560743567365@1635829258162/Study-design-Subjects-in-SAD-cohort-4-part-2-were-dosed-in-the-fed-state-all-others.png)
Study design. Subjects in SAD cohort 4, part 2, were dosed in the fed... | Download Scientific Diagram
![A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy | Advances in Therapy A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy | Advances in Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-021-01757-z/MediaObjects/12325_2021_1757_Fig1_HTML.png)
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy | Advances in Therapy
STATISTICAL ANALYSIS PLAN Protocol PQ-010-001 PHASE 1B, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, DOSE ESCALATION STUDY TO
![Illustrative 'accelerated' development 'go/no-go' plan of an add-on... | Download Scientific Diagram Illustrative 'accelerated' development 'go/no-go' plan of an add-on... | Download Scientific Diagram](https://www.researchgate.net/publication/259269580/figure/fig2/AS:667595258753033@1536178521489/Illustrative-accelerated-development-go-no-go-plan-of-an-add-on-treatment-CIAs.png)